Correction to: Risk factors for lymphopenia in patients with relapsing–remitting multiple sclerosis treated with dimethyl fumarate

被引：0
|
作者：
Fabian Sierra Morales
Igor J. Koralnik
Shiva Gautam
Soleil Samaan
Jacob A. Sloane
机构：
[1] Harvard Medical School,Division of Neuro
[2] Harvard Medical School,Immunology, Department of Neurology, Beth Israel Deaconess Medical Center, Multiple Sclerosis Center
[3] Harvard Medical School,Division of Biostatistics, Department of Medicine, Beth Israel Deaconess Medical Center
来源：
Journal of Neurology | 2020年 / 267卷
关键词：
D O I：
暂无
中图分类号：
学科分类号：
摘要：
Unfortunately, the given name and family name of first author was incorrectly tagged in the xml data, therefore it is abbreviated wrongly as “Morales FS” in Pubmed. The correct given name is Fabian and family name is Sierra Morales. Auhtor name should be abbreviated as Sierra Morales F.
引用
收藏
页码：132 / 132
相关论文
共 50 条
  • [31] Comparative analysis of dimethyl fumarate and teriflunomide in relapsing-remitting multiple sclerosis
    Mueller, J.
    Schaedelin, S.
    Benkert, P.
    Haenni, P.
    Schmid, J.
    Derfuss, T.
    Kuhle, J.
    Yaldizli, O.
    MULTIPLE SCLEROSIS JOURNAL, 2021, 27 (2_SUPPL) : 676 - 676
  • [32] In-depth Immunophenotyping of newly diagnosed Relapsing Remitting Multiple Sclerosis (RRMS) patients and pPatients treated with dimethyl fumarate.
    Nakhaei-Nejad, M.
    Barilla, D.
    Blevins, G.
    Hirschfeld, A.
    Giuliani, F.
    MULTIPLE SCLEROSIS JOURNAL, 2016, 22 : 878 - 878
  • [33] An interim analysis of quality of life in patients with relapsing-remitting multiple sclerosis treated with delayed-release dimethyl fumarate
    Sarda, S. P.
    Kita, M.
    Fox, R. J.
    Gold, R.
    Giovannoni, G.
    Phillips, T.
    Okwuokenye, M.
    Kong, J.
    Zhang, R.
    Kurukulasuriya, N. C.
    Kappos, L.
    MULTIPLE SCLEROSIS JOURNAL, 2014, 20 : 413 - 414
  • [34] Cost-Effectiveness of Dimethyl Fumarate Compared to Teriflunomide for Relapsing Remitting Multiple Sclerosis Patients in Italy
    Mantovani, Lorenzo Giovanni
    Cortesi, Paolo Angelo
    Cardillo, Alessandra
    Santoni, Laura
    Prosperini, Luca
    FARMECONOMIA-HEALTH ECONOMICS AND THERAPEUTIC PATHWAYS, 2022, 23 (01) : 13 - 28
  • [35] Dimethyl fumarate decreases serum neurofilament light chain in relapsing-remitting multiple sclerosis patients
    Sainz De La Maza, S.
    Walo Delgado, P. E.
    Villarrubia, N.
    Monreal, E.
    Espino, M.
    Fernandez-Velasco, J. I.
    Masjuan, J.
    Costa-Frossard, L.
    Villar, L. M.
    MULTIPLE SCLEROSIS JOURNAL, 2020, 26 (3_SUPPL) : 149 - 150
  • [36] Dimethyl Fumarate Dose Reduction in Lymphopenic Relapsing Remitting Multiple Sclerosis Patients: Clinical and MRI Outcomes
    Wong, Ka-Ho
    Bacharach, Rae
    Marini, Erica
    Tram Nguyen
    Clardy, Stacey
    Cortez, Melissa
    DeWitt, L.
    Greenlee, John
    Klein, Julia
    Soldan, M. Paz
    Steffens, John
    Rose, John
    NEUROLOGY, 2019, 92 (15)
  • [37] Dimethyl fumarate withdrawalFulminant rebound of relapsing-remitting multiple sclerosis: case report
    Reactions Weekly, 2018, 1711 (1) : 108 - 108
  • [38] Safety and persistence of dimethyl fumarate as a treatment for relapsing-remitting multiple-sclerosis
    Boullosa-Lale, Silvia
    Gonzalez-Freire, Lara
    Martinez-Martinez, Luciano
    Crespo-Diz, Carlos
    FARMACIA HOSPITALARIA, 2021, 45 (02) : 73 - 76
  • [39] Oral fumarate for relapsing-remitting multiple sclerosis
    Sorensen, Per Soelberg
    Sellebjerg, Finn
    LANCET, 2008, 372 (9648): : 1447 - 1448
  • [40] Interim analysis of quality of life in patients with relapsing remitting multiple sclerosis treated with BG-12 (dimethyl fumarate) in the ENDORSE study
    Kita, M.
    Fox, R. J.
    Gold, R.
    Giovannoni, G.
    Phillips, J. T.
    Sarda, S. P.
    Kong, J.
    Zhang, R.
    Viglietta, V.
    Sheikh, S. I.
    Kappos, L.
    MULTIPLE SCLEROSIS JOURNAL, 2013, 19 (11) : 530 - 530
12345